Research has indicated that the SH3 domain of the ABL1 protein negatively regulates its function, and high expression of ABL1 often indicates poor prognosis, which is commonly observed in chronic myeloid leukemia, but it is less studied in other cancers [42]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.